Changes in immunity characteristics in patients with small (T1) choroidal melanoma after a course of 810-nm diode laser TTT delivered using the developed methodology  

I.V. Tsukanova, Junior Research Associate; S.I. Poliakova, Dr Sc (Med); L.N. Velichko, Cand Sc (Med); A.V. Bogdanova, Cand Sc (Biol)

SI " The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine”; Odesa (Ukraine)

E-mail: inna.sister@gmail.com

TO CITE THIS ARTICLE: Tsukanova IV, Poliakova SI, Velichko LN, Bogdanova AV. Changes in immunity characteristics in patients with small (T1) choroidal melanoma after a course of 810-nm diode laser TTT delivered using the developed methodology. J.ophthalmol.(Ukraine).2019;4:28-32. http://doi.org/10.31288/oftalmolzh201942832


Background: Immune response is an important factor for efficacy of choroidal melanoma (CM) treatment. Adequate uveal melanoma (UM) organ-saving treatment and treatment efficacy monitoring requires determining the interaction pattern between immune and tumor cells.

Purpose: To investigate changes in immune characteristics in patients with small T1 CM (measuring ≤ 3 mm in thickness and ≤ 12 mm in basal dimension) after a course of 810-nm diode laser transpupillary thermotherapy (TTT) delivered using the developed methodology.

Materials and Methods: We determined immune system characteristics in 35 patients (9 men (25.7%) and 26 women (24.3%); mean age, 53.9 (12.1) years) with small (T1) CM before and after a course of 810-nm diode laser TTT delivered using the developed methodology. 

Results: Some characteristics (absolute white blood cell count, absolute and relative CD8+ T cell counts, absolute and relative phagocytic neutrophil activity, absolute and relative CD19+ B cell counts, IgA, IgM, and IgG) decreased, whereas others (relative white blood cell count, absolute and relative CD3+ T cell counts, absolute and relative CD4+ T helper counts, CD4+/CD8+ T-cell ratio, and absolute and relative CD16+ NK cell counts) increased after treatment. However, these changes were not statistically significant, excepting that relating to CD4+/CD8+ T-cell ratio (F=7.9; p = 0.05).

Conclusion: 810-nm diode laser transpupillary thermotherapy (TTT) delivered using the developed methodology results in a shift in specific antitumor immune response patterns with a suppression of cytolytic CD8+ T cell response, which requires administering immunocorrective therapy as early as the initial stage of the disease.

Keywords: small T1 choroidal melanoma, transpupillary thermotherapy, cell-mediated and humoral immunity


1.Berezhnaya NM. [Role of immune system cells in tumor microenvironment. II. Interaction of the immune system cells with other microenvironment components]. Onkologiia. 2009;11(2):86–93. Russian.

2.Blokade of PD-L1 (B7-H1) augments human tumor-spescific T cell responses in vitro.  Int J Cancer. 2006 Jul 15;119(2):317-27.

Crossref    PubMed

3.Mantovani A, Germano G, Marchesi F, et al. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol. 2011 Sep;41(9):2522-5. 

Crossref   PubMed 

4.Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. 

Crossref   PubMed   

5.Singh AD, Aronow ME, Sun Y, et al. Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest Ophthalmol Vis Sci. 2012 Jun 5;53(7):3331-9. 

Crossref    PubMed

6.de Waard-Siebinga I, Creyghton WM, Kool J. Effects of interferon alfa and gamma on human uveal melanoma cells in vitro. Br J Ophthalmol. 1995 Sep;79(9):847-55.

Crossref    PubMed  

7.Fidler IJ, Poste G. The “seed and soil” hypothesis revisited. Lancet Oncol. 2008 Aug;9(8):808. 


8.de Waard-Siebinga I, Hilders CG, Hansen BE, et al. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 1996 Jan;234(1):34-42.

Crossref   PubMed  

9.Fridman WH, Galon J, Pages F, et al. Prognostic and predictive impact of intra and peritumoral immune infiltrates. Cancer Res. 2011 Sep 1;71(17):5601-5. 

Crossref    PubMed 

10.Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet. 2001 Feb 17;357(9255):539-45.


11.Bulgakova ES. [Treatment of small choroidal melanomas with diode laser transpupillary thermotherapy]. [Abstract of Cand Sc (Med) Thesis]. Moscow: Helmholtz Research Institute for Eye Diseases; 2005. 25 p. Russian.

12.Bukhtiiarova NV. [Transpupillary thermotherapy in the multicomponent organ-sparing treatment of choroidal melanoma]. [Abstract of Cand Sc (Med) Thesis]. Cheliabinsk: Ural State Medical Academy of Additional Education; 2006. 22 p. Russian.

13.Volkov VV. [Laser treatment of intraocular melanoma]. Russkii meditsinskii zhurnal. 2001;2(1):3–7. Russian.

14.Mazunin IIu. [New treatment methods in pathologies of the choroid and retina including the use of subthreshold power od fiode infrared laser radiation]. Vestn Oftalmol. 2005 Jan-Feb;121(1):49-54. Review. Russian.

15.Iarovoi AA, Linnik LF, Magaramov DA, et al. [Diode laser transpupillary thermotherapy: the potential for the treatment of small choroidal melanomas]. Russkii meditsinskii zhurnal. 2004;5(2):77–81. Russian. 

16.Ushenina LA. [Optimization of laser treatment for early choroidal melanoma]. [Cand Sc (Med) Thesis]. Cheliabinsk: Ural State Medical Academy of Additional Education; 2008. 114 p. Russian.

17.De Potter P, Levecq L. [Transpupillary thermotherapy in the treatment of choroid]. J Fr Ophthalmology. 2001 Nov;24(9):937-43. French.

18.Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005 Dec;123(12):1639-43.

Crossref   PubMed

19.De Potter P. [Treatment of intraocular melanoma: new concepts]. Bull Men Acad R Med Belg. 2003;158(1-2):103-11; discussion 111-2. French.

20.Kiratli H, Bilgic S. Peripheral subretinal pigment accumulation following transpupillary thermotherapy for choroidal melanoma. Ophthalmic Surg Lasers Imaging. 2008 Jan-Feb;39(1):60-2.

Crossref   PubMed   

21.Shields CL, Shields JA, Kiratli H, et al. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmol. – 1995 Sep;102(9):1351-61.


22.Buiko AS, translator. [Choroidal melanoma classification]. Oftalmol Zh. 2010;(6):20-30. Russian.

23.Currie ZI, Rennie IG, Talbot JF. Retinal vascular changes associated with transpupillary thermotherapy for choroidal melanomas. Retina. 2000;20(6):620-6.

Crossref   PubMed  

24.Damato B, Lecuona K. Conservation of Eyes with Choroidal Melanoma by a Multimodality Approach to Treatment. An audit of 1632 Patients. Ophthalmology. 2004 May;111(5):977-83.

Crossref   PubMed   

25.Damato B. Developments in the management of uveal melanoma. Clin Experiment Ophthalmol. 2004 Dec;32(6):639-47.

Crossref    PubMed

26.Journee–de Korver JG,  Oosterhuis JA, De Wolff–Rouendaal D, Kemme H. Histopathological findings in human choroidal melanomas after transpupillary thermotherapy. Brit J Ophthal. 1997 Mar;81(3):234-9. 

Crossref    PubMed  

27.Shields CL, Shields JA, Cater J. Plaque radiotherapy for uveal melanoma: long–term visual outcome in 1106 consecutive patients. Arch Ophthal. 2000;118:1219–28.

Crossref   PubMed

28.Shields CL, Shields JA. Clinical features of small choroidal melanoma. Curr Opin Ophthalmol. 2002 Jun;13(3):135-41.

Crossref   PubMed 

29.Shields CL, Shields JA, Cater J, et al. Transpupillary Thermotherapy for Choroidal Melanoma: tumor control and visual results in 100 consecutive cases. Ophthalmology. 1998 Apr;105(4):581-90.


30.Shields CL, Shields JA, Peres N, et al. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology. 2002 Feb;109(2):225-34.


31.Gusev AG. [Use of immune modulators in multicomponent treatment of malignant ocular tumors]. Cand Sc (Med) Thesis Abstract. Moscow; 1992. Russian.

32.Likhvantseva VG. [Role of cytokines in the pathogenesis, prognosis and treatment of choroidal melanoma]. Dr Sc (Med) Dissertation Abstract. Moscow; 2001. Russian.

33.Maletskyi AP. [Efficacy of organ-saving treatment of uveal melanoma patients depending on clinical and morphological characteristics of the tumor and body resistance to the tumor]. Dr Sc (Med) Dissertation Abstract. Odesa: Filatov Institute of Eye Disease;2001. 32 p. Ukrainian.

34.Pasyechnikova NV, Naumenko VO, Poliakova SI, Tsukanova IV. [Information Bulletin No. 22 of 25.11.2015, p.145, based on Pat. of Ukraine №102,890 issued 18.05.2015]. [Method for treatment of patients with small (T1) choroidal melanoma]. Owner: State Institution Filatov Institute of Eye Diseases and Tissue Therapy NAMS of Ukraine. Ukrainian.

35.Degtiarenko TV, Bushueva NN, Usov NI. [Methodological guidelines for prompt primary assessment of immune status]. Odessa; 1992. Russian.

36.Gluzman DF, Skliarenko LM, Nadgornaia VA, Kriachok IA. [Immunocytochemistry in tumor diagnosis]. Kyiv: Morion;2003. Russian.

37.Poliakova SI, Velichko LN, Bogdanova AV, Tsukanova IV. [Natural antitumor resistance of the organism condition of patients with uveal melanoma of small sizes]. Oftalmol Zh. 2016;(1):27-38. Russian.


38.De Potter P, Jamart J. Adjuvant Indocyanine Green in Transpupillary Thermotherapy for Choroidal Melanoma. Ophthalmology. 2003 Feb;110(2):406-13; discussion 413-4.


The authors certify that they have no conflicts of interest in the subject matter or materials discussed in this manuscript.